Publications by authors named "Erica VanderPorten"

Claim this Profile
I
Implementation of the CYP Index for the Design of Selective Tryptophan-2,3-dioxygenase Inhibitors.
Brendan T Parr, Richard Pastor, Benjamin D Sellers, Zhonghua Pei, Firoz A Jaipuri, Erica C VanderPorten

ACS Med Chem Lett· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative Determination of Protein-Ligand Affinity by Size Exclusion Chromatography Directly Coupled to High-Resolution Native Mass Spectrometry.
Chengfeng Ren, Aaron O Bailey, Erica VanderPorten, Angela Oh, Wilson Phung

Anal Chem· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aminoisoxazoles as Potent Inhibitors of Tryptophan 2,3-Dioxygenase 2 (TDO2).
Zhonghua Pei, Rohan Mendonca, Lewis Gazzard, Richard Pastor, Leanne Goon, Erica VanderPorten

ACS Med Chem Lett· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Small-Molecule Noncovalent Binders Utilizing SAMDI Technology.
Erica C VanderPorten, Michael D Scholle, John Sherrill, John C Tran, Yichin Liu

SLAS Discov· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of potent, selective KDM5 inhibitors.
Victor S Gehling, Steven F Bellon, Jean-Christophe Harmange, Yves LeBlanc, Florence Poy, Erica VanderPorten

Bioorg Med Chem Lett· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors.
Sharada S Labadie, Peter S Dragovich, Richard T Cummings, Gauri Deshmukh, Amy Gustafson, Erica VanderPorten

Bioorg Med Chem Lett· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of 5-(2,6-dichlorophenyl)-3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.
Sharada Labadie, Peter S Dragovich, Jinhua Chen, Benjamin P Fauber, Jason Boggs, Erica VanderPorten

Bioorg Med Chem Lett· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.
Peter S Dragovich, Benjamin P Fauber, Jason Boggs, Jinhua Chen, Laura B Corson, Erica VanderPorten

Bioorg Med Chem Lett· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Label-free high-throughput assays to screen and characterize novel lactate dehydrogenase inhibitors.
Erica Vanderporten, Lauren Frick, Rebecca Turincio, Peter Thana, William Lamarr

Anal Biochem· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of 2-amino-5-aryl-pyrazines as inhibitors of human lactate dehydrogenase.
Benjamin P Fauber, Peter S Dragovich, Jinhua Chen, Laura B Corson, Charles Z Ding, Erica VanderPorten

Bioorg Med Chem Lett· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase.
Peter S Dragovich, Benjamin P Fauber, Laura B Corson, Charles Z Ding, Charles Eigenbrot, Erica VanderPorten

Bioorg Med Chem Lett· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential effects of divalent manganese and magnesium on the kinase activity of leucine-rich repeat kinase 2 (LRRK2).
Brian Lovitt, Erica C Vanderporten, Zejuan Sheng, Haitao Zhu, Jake Drummond

Biochemistry· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model.
Erica C VanderPorten, Pietro Taverna, Jennifer N Hogan, Marcus D Ballinger, W Michael Flanagan

Mol Cancer Ther· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors.
Emily J Hanan, Raymond V Fucini, Michael J Romanowski, Robert A Elling, Willard Lew, Erica C VanderPorten

Bioorg Med Chem Lett· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.
Raymond V Fucini, Emily J Hanan, Michael J Romanowski, Robert A Elling, Willard Lew, Erica C VanderPorten

Bioorg Med Chem Lett· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis